Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma

Anaplastic Large Cell Lymphoma (ALCL) is a subtype of non-Hodgkin lymphoma frequently driven by the chimeric tyrosine kinase NPM-ALK, generated by the t (2,5)(p23;q35) translocation. While ALK+ ALCL belongs to mature T cell lymphomas, loss of T cell identity is observed in the majority of ALCL secon...

Full description

Bibliographic Details
Main Authors:	Giulia Mura, Elif Karaca Atabay, Matteo Menotti, Cinzia Martinengo, Chiara Ambrogio, Gloria Giacomello, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Roberto Chiarle, Claudia Voena
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	anaplastic large cell lymphoma ALK CD45 phosphatases resistance tyrosine kinase inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1085672/full

Similar Items

ALK signaling and target therapy in anaplastic large cell lymphoma
by: Fabrizio eTabbo, et al.
Published: (2012-05-01)

Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience
by: Yingyi He, et al.
Published: (2023-03-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
by: Dennis Christoph Harrer, et al.
Published: (2020-10-01)

Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models
by: Debasis Das, et al.
Published: (2024-12-01)

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
by: Voena, C, et al.
Published: (2007)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

ALK+ Anaplastic Large Cell Lymphoma of Null Cell Phenotype with Leukemic Transformation and Leukemoid Reaction
by: Shih-Sung Chuang, et al.
Published: (2019-11-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)

Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
by: Muthiah Vaikundaraja Indhuja, et al.
Published: (2024-04-01)

Leukemic phase as the initial presentation of ALK‐positive anaplastic large‐cell lymphoma complicated by lactic acidosis
by: Noriharu Nakagawa, et al.
Published: (2023-02-01)

Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
by: Eric Lowe, et al.
Published: (2024-04-01)

ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature
by: Weerapat Owattanapanich, et al.
Published: (2017-05-01)

PRIMARY PALATAL ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: RARITY TREATED SUCCESSFULLY WITH BRENTUXIMAB VEDOTIN
by: Müjgan Çözeli, et al.
Published: (2024-12-01)

Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma
by: Indu Agarwal, et al.
Published: (2020-05-01)

Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman—Report of a Case with 9-Year Survival
by: Carlos Santonja, et al.
Published: (2023-09-01)

Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
by: Vivek Yadav, et al.
Published: (2024-04-01)

Case report: a unique pediatric case of a primary CD8 expressing ALK-1 positive anaplastic large cell lymphoma of skeletal muscle
by: Gaiser Timo, et al.
Published: (2012-04-01)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
by: Huan Zhang, et al.
Published: (2021-11-01)

ALK-Positive Histiocytosis: A Case Report and Literature Review
by: Omar Issa JABER, et al.
Published: (2021-05-01)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
by: Makito Tanaka, et al.
Published: (2023-05-01)

Exploiting signaling rewiring in cancer cells with co‐existing oncogenic drivers
by: Roberto Chiarle, et al.
Published: (2023-11-01)

Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
by: Melanie R. Hassler, et al.
Published: (2016-10-01)

Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
by: Claudia Parisi, et al.
Published: (2024-12-01)

A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
by: Stefanie Kreutmair, et al.
Published: (2022-05-01)

A Case of Anaplastic Large Cell Lymphoma Misdiagnosed with Keloid
by: Kong D, et al.
Published: (2023-05-01)

Primary anaplastic large cell lymphoma of caecum and ascending colon
by: Sistla Radha, et al.
Published: (2021-01-01)

Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma
by: Kai Yin, et al.
Published: (2020-02-01)

Primary CNS ALK-negative anaplastic large cell lymphoma: A case report and review of the literature
by: Amy L. Brady, DO, et al.
Published: (2024-01-01)

Granulomatous Inflammation in a Patient with ALK-Negative Anaplastic Large Cell Lymphoma
by: Özlem Kandemir Alibakan, et al.
Published: (2022-02-01)

Identification of NPM-ALK-interacting proteins involved in the transformation of anaplastic lymphomas
by: Voena, C, et al.
Published: (2005)

Identification of NPM-ALK-interacting proteins involved in the transformation of anaplastic lymphomas
by: Voena, C, et al.
Published: (2005)

Minimal Disseminated Disease Continues to Impact Outcomes Even in the Era of Targeted Therapy in Childhood ALK+ Anaplastic Large Cell Lymphoma, What More Do We Have to Offer?
by: Nidhi Dhariwal, et al.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

Bilateral breast metastases from anaplastic lymphoma kinase-positive lung cancer in a male: a case report
by: Sumire Koh, et al.
Published: (2024-09-01)

Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases
by: Yosuke Murakami, et al.
Published: (2024-02-01)

A Rare Case of Primary Pulmonary Anaplastic Large Cell Lymphoma
by: Joana Carvalho, et al.
Published: (2019-09-01)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
by: Minsuk Kwon, et al.
Published: (2022-08-01)

Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression
by: Yusuke Yamashita, et al.
Published: (2020-05-01)

Editorial: Tyrosine kinases and phosphatases in T- cell malignancies
by: Melania Tesio
Published: (2024-02-01)